基因1型慢性丙型肝炎初治患者获得持续病毒学应答的相关因素研究

doi:10.3969/j.issn.1672-5069.2011.06.008

Abstract

Abstract: Objective To study the related factors of a sustained virologic response in patients with chronic hepatitis C genotype 1.Methods A total of 73 de novo chronic hepatitis C genotype 1 patients received combination therapy of peginterferon alpha and ribavirin for 24 to 48 weeks and were followed-up for 24 weeks.Results 47.9% of patient achieved an early viral response and 38.4% of patients got an sustained viral response;Statistical analysis indicated that patients with lower baseline HCV load（<8×105 IU/ml），lower body mass index and early viral response would achieve sustained viral response（SVR）.Conclusion Baseline HCV load， BMI and early viral response are related to achieving SVR in de novo hepatitis C genotype 1 patients.

Key words: Hepatitis C, Sustained viral response, Genotype

XIAO Fei，MA Ke，HUANG Jiaquan. Factors of sustained virologic response in de novo patiants with chronic hepatitis C genotype 1[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2011, 14(6): 420-421.

References

[1] 中华医学会肝病学分会和传染病与寄生虫病学分会.慢性丙型肝炎防治指南[J]. 中华肝脏病杂志 2004，12（4）：194-198.
[2] MANNS MP，MCHUTCHISON JG，GORDON SC，et al.Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C:a randomised trial[J]. Lancet，2001，358:958-965.
[3] HADZIYANNIS SJ，SETTE H JR，MORGAN TR，et al.Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C:a randomized study of treatment duration and ribavirin dose[J]. Ann Intern Med，2004，140:346-355.
[4] ZEUZEM S，BUTI M，FERENCI P，et al.Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia[J]. J Hepatol，2006，44:97-103.
[5] BERG T，VON WAGNER M，NASSER S，et al.Extended treatment duration for hepatitis C virus type 1:comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin[J]. Gastroenterology，2006，130:1086-1097.
[6] 谢尧，徐道振，陆志檬，等.慢性丙型肝炎抗病毒治疗应答独立预测因子的研究[J]. 中华肝脏病杂志，2004，12（8）:485-488.
[7] 朱斌，张平，王昕红，等.血清瘦素水平、胰岛素抵抗与慢性丙型肝炎抗病毒应答的相关性[J]. 中华肝脏病杂志，2006，14（12）：887-889.
[8] MOUCARE R，RIPAULT MP，MARTINOT-PEIGNOUX M，et al. Insulin resistance and geographical origin:major predictors of liver fibrosis and response to peginterferon and ribavirin in HCV-4[J]. Gut，2009，58（12）:1662-1669.
[9] SUPPIAH V，MOLDOVAN M，AHLENSTIEL G，et al.IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy[J]. Nat Genet，2009，41（10）:1100-1104.
[10] TANAKA Y，NISHIDA N，SUGIYAMA M，et al.Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C[J]. Nat Genet，2009，41（10）:1105-1109.
[11] THOMPSON AJ，MUIR AJ，SULKOWSKI MS，et al.Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 Hepatitis C virus[J]. Gatroenterology，2010，139（1）: 120-129.
[12] MCCARTHY J，LI J，THOMPSON A，et al.Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin[J]. Gastroenterology，2010，138:2307-2314.
[13] KAWAOKA T，HAYES CN，OHISHI W，et al.Predictive value of the IL28B polymorphism on the effect of interferon therapy in chronic hepatitis C patients with genotypes 2a and 2b[J]. J Hepatol，2011，54（3）:408-414.
[14] AKUKA N，SUZUKI F，HIRAKAWA M，et al.Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin[J]. Hepatology，2010，52（2）:421-429.
[15] OCHI H，MAEKAWA T，ABE H，et al.IL-28B predicts response to chronic hepatitis C therapy--fine-mapping and replication study in Asian populations[J]. J Gen Virol，2011，92（5）:1071-1081.

Factors of sustained virologic response in de novo patiants with chronic hepatitis C genotype 1

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Pan Meimin, Li Wenjuan, Jiang Fangqing, et al.. Changes of serum IL-17A,fibroblast growth factor and IL-7 levels in patients with hepatitis C virus infection [J]. Journal of Practical Hepatology, 2019, 22(6): 840-843.
[2]	Yang Caiyong, Chen Na, Li Kui, et al.. Clinical significance of peripheral blood Treg and Th17 cells in patients with chronic hepatitis C and hepatitis C-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(6): 868-871.
[3]	Deng Haohui, Li Xiaoqiang, Gao Hongbo, et al. Comparison of HCV genotypes in patients with HIV/HCV co-infection and HCV mono-infection in Guangzhou [J]. Journal of Practical Hepatology, 2019, 22(5): 656-659.
[4]	Liu Li，Li Junyi，Du Yingrong. Efficacy and safety of sofosbuvir/daclatasvir in the treatment of patients with chronic hepatitis C and hepatitis C cirrhosis:An real-world study [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 361-364.
[5]	Jiang Yi, Liu Bing. Comparison of clinical features and histopathological activity index between patients with chronic hepatitis B and chronic hepatitis C [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 188-191.
[6]	Wu Jing, Dong Baoji, Wu Chao. Comparison of PD-1 receptor on peripheral blood follicular helper T lymphocyte surface in chronic hepatitis C patients with low and high serum viral loads [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 192-195.
[7]	Wu Yaping, Zhou Bingqing, Jiang Peili. Risk factors of severe hepatic fibrosis in patients with chronic hepatitis C with previous paid blood donation [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 196-199.
[8]	Yang Zhenjie, Li Hongtao, Wang Jian, Li Xia, Chen Yuan. Efficacy of combination of pegylated interferon-α-2a and ribavirin in treatment of patients with compensated hepatitis C cirrhosis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 232-235.
[9]	Zhang Huanhuan, Yang Huan, Shen Silan, et al.. Distribution of HBV genotypes and drug-resistant mutations in patients with chronic hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 41-44.
[10]	Hou Chunyang, Ma Yumei, Li Fangzhi.. Clinical efficacy of peg-IFNα and ribavirin combination in treating patients with chronic hepatitis C and genotype one and six infection [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 53-56.
[11]	Zhao Peng, Wang Lei.. Comparison of therapeutic efficacy of pegylated interferon-α in treatment of patients with different hepatitis C viral genotype infection [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 57-60.
[12]	Xu Xi, Dang Yinli, Wu Shuo.. Construction and expression of recombinant eukaryotic expression vector of HCV infection related interferon λ4 [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 833-836.
[13]	Ji Xiaoqin, Gong Jian.. Clinical features and antiviral treatment of elderly patients with chronic hepatitis C [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 995-998.
[14]	Zhou Sisi, Shen Youxiu, Li Juan, et al.. Changes of peripheral blood Th17 and Treg cells and their related serum cytokines in patients with chronic hepatitis C and liver cirrhosis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(5): 689-692.
[15]	Cao Fenghua, Jing Jisheng, Zhao Wei, et al.. Clinical efficacy and safety of large dose of domestic interferon-α2b and ribavirin in the treatment of patients with chronic hepatitis C [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(5): 729-732.